Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285684531> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W4285684531 abstract "Aducanumab (ADUHELMTM) was approved for the treatment of Alzheimer's disease (AD) in the US. This approval was supported by an effect on the cerebral amyloid plaque load and evidence of cognitive efficacy to be confirmed in post-marketing trials. Other anti-amyloid antibodies are under investigation in phase III (donanemab, lecanemab, gantenerumab) and have shown preliminary evidence of a cognitive benefit in phase II trials. Although these agents target a small segment of patients with mild cognitive impairment due to AD or mild AD dementia, their advent will change the design of future clinical trials both for anti-amyloid and non-amyloid drugs. These changes will promote the selection of patients in clinical trials by amyloid and tau biomarkers that identify patients with appropriate biology and may follow the treatment response to approved amyloid antibodies. The use of these agents creates the opportunity to test combined drug therapies and to conduct comparative assessments with innovative therapies and newly approved drugs available in clinical practice. Blood-based AD biomarkers should be implemented in research and could facilitate the recruitment into clinical trials. Anti-amyloid antibodies will have positive (e.g., more early diagnosis) and negative impacts (some subjects will be reluctant to participate in trials and risk assignment to placebo) on AD trials in the immediate future. We present the results of the CTAD Task Force on this topic, in Boston, November 6, 2021." @default.
- W4285684531 created "2022-07-17" @default.
- W4285684531 creator A5001479532 @default.
- W4285684531 creator A5014052828 @default.
- W4285684531 creator A5022462599 @default.
- W4285684531 creator A5060487287 @default.
- W4285684531 creator A5062695564 @default.
- W4285684531 date "2022-01-01" @default.
- W4285684531 modified "2023-10-14" @default.
- W4285684531 title "The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report" @default.
- W4285684531 doi "https://doi.org/10.14283/jpad.2022.48" @default.
- W4285684531 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35841240" @default.
- W4285684531 hasPublicationYear "2022" @default.
- W4285684531 type Work @default.
- W4285684531 citedByCount "5" @default.
- W4285684531 countsByYear W42856845312022 @default.
- W4285684531 countsByYear W42856845312023 @default.
- W4285684531 crossrefType "journal-article" @default.
- W4285684531 hasAuthorship W4285684531A5001479532 @default.
- W4285684531 hasAuthorship W4285684531A5014052828 @default.
- W4285684531 hasAuthorship W4285684531A5022462599 @default.
- W4285684531 hasAuthorship W4285684531A5060487287 @default.
- W4285684531 hasAuthorship W4285684531A5062695564 @default.
- W4285684531 hasBestOaLocation W42856845311 @default.
- W4285684531 hasConcept C126322002 @default.
- W4285684531 hasConcept C142724271 @default.
- W4285684531 hasConcept C143998085 @default.
- W4285684531 hasConcept C17744445 @default.
- W4285684531 hasConcept C204787440 @default.
- W4285684531 hasConcept C27081682 @default.
- W4285684531 hasConcept C2777633098 @default.
- W4285684531 hasConcept C2779134260 @default.
- W4285684531 hasConcept C2779483572 @default.
- W4285684531 hasConcept C2984863031 @default.
- W4285684531 hasConcept C2985871740 @default.
- W4285684531 hasConcept C3116431 @default.
- W4285684531 hasConcept C535046627 @default.
- W4285684531 hasConcept C71924100 @default.
- W4285684531 hasConceptScore W4285684531C126322002 @default.
- W4285684531 hasConceptScore W4285684531C142724271 @default.
- W4285684531 hasConceptScore W4285684531C143998085 @default.
- W4285684531 hasConceptScore W4285684531C17744445 @default.
- W4285684531 hasConceptScore W4285684531C204787440 @default.
- W4285684531 hasConceptScore W4285684531C27081682 @default.
- W4285684531 hasConceptScore W4285684531C2777633098 @default.
- W4285684531 hasConceptScore W4285684531C2779134260 @default.
- W4285684531 hasConceptScore W4285684531C2779483572 @default.
- W4285684531 hasConceptScore W4285684531C2984863031 @default.
- W4285684531 hasConceptScore W4285684531C2985871740 @default.
- W4285684531 hasConceptScore W4285684531C3116431 @default.
- W4285684531 hasConceptScore W4285684531C535046627 @default.
- W4285684531 hasConceptScore W4285684531C71924100 @default.
- W4285684531 hasLocation W42856845311 @default.
- W4285684531 hasLocation W42856845312 @default.
- W4285684531 hasLocation W42856845313 @default.
- W4285684531 hasLocation W42856845314 @default.
- W4285684531 hasOpenAccess W4285684531 @default.
- W4285684531 hasPrimaryLocation W42856845311 @default.
- W4285684531 hasRelatedWork W1481122508 @default.
- W4285684531 hasRelatedWork W2009588589 @default.
- W4285684531 hasRelatedWork W2078461035 @default.
- W4285684531 hasRelatedWork W2150424301 @default.
- W4285684531 hasRelatedWork W2280637608 @default.
- W4285684531 hasRelatedWork W2561267217 @default.
- W4285684531 hasRelatedWork W4205433248 @default.
- W4285684531 hasRelatedWork W4233016836 @default.
- W4285684531 hasRelatedWork W4312389194 @default.
- W4285684531 hasRelatedWork W4379621630 @default.
- W4285684531 isParatext "false" @default.
- W4285684531 isRetracted "false" @default.
- W4285684531 workType "article" @default.